Monte Rosa Therapeutics shares jumped over 50% in pre-market trade after interim Phase 1 results for MRT-8102 showed strong anti-inflammatory effects in patients with elevated cardiovascular risk, with 94% achieving CRP levels linked to lower risk. Safety was favorable, and the company said partner Novartis is expected to begin multiple Phase 2 studies of MRT-6160.